A panel delves into pivotal clinical trials leading to therapies approved for diffuse large B-cell lymphoma (DLBCL) and provides insights on trial design, patient cohorts, response rates, duration, and toxicity profiles, highlighting efficacy nuances.
Experts explore early outcomes and patient candidacy factors for bispecific antibody therapy in diffuse large B-cell lymphoma (DLBCL) and discuss responses, real-world evidence, trends in patient outcomes, and selection biases.